News
Public · Published
RBC Capital maintains Regeneron Pharmaceuticals at Sector Perform, raises price target to $913 from $810
RBC Capital kept Regeneron Pharmaceuticals at Sector Perform, meaning it expects performance broadly in line with the sector, and raised its price target to $913 from $810. That is a 12.7% increase, but the new target was 1.6% below the stock's October 30 closing price of $927.89.
Published:
Updated:
What happened
RBC Capital kept Regeneron Pharmaceuticals at Sector Perform, meaning it expects performance broadly in line with the sector, and raised its price target to $913 from $810. That is a 12.7% increase, but the new target was 1.6% below the stock’s October 30 closing price of $927.89.
Confirmed
Global impact / market context
The higher target signals RBC sees more value than before, but its target still sits below the cited closing price. If investors treat analyst targets as guidance, this gap could temper expectations for share gains and influence buying or selling decisions around Regeneron.
Analyst inference
The five other recent analyst targets listed span $925 to $1,175, putting RBC’s $913 target below that range. This spread shows differing views on Regeneron’s prospects; the article gives no company results or business changes to explain the disagreement.
Confirmed
What to watch
- Compare later analyst ratings and targets with RBC’s $913 figure to see whether its below-market view persists or other analysts move closer to it. Analyst inference
- Watch for any change in RBC’s Sector Perform rating or price target; the article reports no planned revision, so a future change is not confirmed. Analyst inference
- Track Regeneron’s share price against the $913 target and the cited $927.89 close; the article does not report subsequent trading or investor reactions. Analyst inference
Evidence
- Original source link unavailable